Venous thrombosis in oral contraceptive users and the presence of the JAK2 V617F mutation

Thrombosis and Haemostasis

Volumn 99, Issue 3, 2008, Pages 640-642

  Grandone, Elvira ^a   Colaizzo, Donatella ^a   Tiscia, Giovanni L ^a   Vergura, Patrizia ^a   Chinni, Elena ^b   Iannaccone, Luigi ^c   Antinolfi, Iole ^c   Guardascione, Maria A ^c   Margaglione, Maurizio ^a,b  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

^c CARDARELLI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIANE; DROSPIRENONE PLUS ESTRADIOL; ETHINYLESTRADIOL PLUS GESTODENE; JANUS KINASE 2; ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; ANTITHROMBIN DEFICIENCY; BLOOD CLOTTING; BLOOD SAMPLING; CONTROLLED STUDY; DNA ISOLATION; DOPPLER ECHOGRAPHY; FEMALE; FIBRINOLYSIS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; HUMAN; HYPERHOMOCYSTEINEMIA; LETTER; MAJOR CLINICAL STUDY; MESENTERIC VEIN THROMBOSIS; MYELOPROLIFERATIVE DISORDER; OCCLUSIVE CEREBROVASCULAR DISEASE; ORAL CONTRACEPTION; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; THROMBOPHILIA; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM;

ADULT; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL, COMBINED; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTRACRANIAL THROMBOSIS; ITALY; JANUS KINASE 2; MESENTERIC VASCULAR OCCLUSION; MESENTERIC VEINS; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDERS; PORTAL VEIN; RISK FACTORS; THROMBOPHILIA; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 42249084906     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-09-0570     Document Type: Letter

References (22)

1. Middeldorp S, Meijers JCM, van den Ende AE, et al. Effects on coagulation of levonorgestrel- and desogestrel- containing low dose oral contraceptives: a cross-over study. Thromb Haemost 2000; 84: 4-8.
2. Tans G, Curvers J, Middeldorp S, et al. A randomized cross-over study on the effects of levonorgestreland desogestrel- containing low dose oral contraceptives on the anticoagulant pathways. Thromb Haemost 2000; 84, 15-21.
3. Vandenbroucke JP, Koster T, Briet E, et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-1457.
4. Jick H, Jick S, Gurewich W, et al. Risk of idiopathic venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-1593.
5. Wu O, Robertson L, Twaddle S, et al; The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Screening for thrombophilia in high-risk situations: a meta-analysis and cost-effectiveness analysis. Br J Haematol 2005; 131: 80-90.
6. Vayá A, Mira Y, Mateo J, et al. Prothrombin G20210A mutation and oral contraceptive use increase upper-extremity deep vein thrombotic risk. Thromb Haemost 2003; 89: 452-457.
7. Dentali F, Crowther M, Ageno W. Thrombophilic abnormalities, oral contraceptives, and the risk of cerebral vein thrombosis: a meta-analysis. Blood 2006; 107: 2766-2773.
8. Harward TR, Green D, Bergan JJ, et al. Mesenteric venous thrombosis. J Vasc Surg 1989; 9: 328-333.
9. Hassan A. Oral contraceptive-induced mesenteric venous thrombosis with resultant intestinal ischemia. J Clin Gastroenterol 1999; 29: 90-95.
10. Abdu RA, Zakhour BJ, Dallis DJ. Mesenteric venous thrombosis - 1911 to 1984. Surgery 1987; 101: 383-388.
11. Kaleya RN, Boley SJ. Mesenteric venous thrombosis. In: Najarian JS, Delaney JP, eds. Progress in gastrointestinal surgery. Chicago: Year Book Medical; 1989: 417-425.
12. Kumar S, Sarr MG, Kamatah. Mesenteric venous thrombosis. N Engl J Med 2001; 345: 1683-1688.
13. Brodmann S, Passweg JR, Gratwohl A, et al. Mye-loproliferative disorders: complications, survival and causes of death. Ann Hematol 2000; 79: 312-318.
14. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
15. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148.
16. Plumé G, Vayá A, Ferrando F, et al. JAK2V617F mutation as a marker of a latent myeloproliferative disorder in a patient with Budd-Chiari syndrome and factor V Leiden mutation. Thromb Haemost 2007; 98: 681-682.
17. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.
18. Colaizzo D, Amitrano L, Tiscia GL, et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost 2007; 5: 55-61.
19. Pierre R, Imbert M, Thiele J, et al. Pathology and genetics of tumors of haematopoietic and lymphoid tissues. In: The World Health Organization classification of tumors. Lyon: IARCPress, 2001: 32-44.
20. Reed DL, Coon WW. Thromboembolism in patients receiving progestational drugs. N Engl J Med 1963; 269: 62-63.
21. Primignani M, Barosi G, Bergamaschi G, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 2006; 44: 1528-1534.
22. De Stefano V, Fiorini A, Rossi E, et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 2007; 5: 708-714.